Laboratory Medicine ›› 2016, Vol. 31 ›› Issue (10): 898-901.DOI: 10.3969/j.issn.1673-8640.2016.010.013
• Orginal Article • Previous Articles Next Articles
Received:
2015-09-19
Online:
2016-10-20
Published:
2016-11-01
CLC Number:
Add to citation manager EndNote|Ris|BibTeX
URL: https://www.shjyyx.com/EN/10.3969/j.issn.1673-8640.2016.010.013
组别 | 例数 | WBC(×109/L) | 血红蛋白(g/L) | 血小板(×109/L) | Neu(×109/L) | Neu百分比(%) |
---|---|---|---|---|---|---|
血流感染组 | 144 | 12.32±6.22 | 103.98±24.38 | 189.37±105.24 | 10.87±6.12 | 84.91±10.11 |
对照组 | 140 | 9.76±4.80 | 107.27±28.09 | 210.77±97.48 | 8.25±8.09 | 79.48±9.83 |
t值 | 4.378 | 1.146 | 1.898 | 3.394 | 4.942 | |
P值 | 0.000 | 0.253 | 0.059 | 0.001 | 0.000 | |
组别 | 例数 | Lym(×109/L) | Lym百分比(%) | NLR | PCT(ng/mL) | CRP(mg/L) |
血流感染组 | 144 | 0.79(0.49~1.13) | 6.70(4.30~12.40) | 12.90(6.54~21.20) | 1.69(0.43~7.45) | 81.15±65.09 |
对照组 | 140 | 1.08(0.73~1.58) | 13.25(7.40~19.37) | 5.97(3.45~11.74) | 0.26(0.05~0.69) | 83.08±60.30 |
t值 | 4.740 | 6.610 | 6.768 | 2.134 | 0.183 | |
P值 | 0.000 | 0.000 | 0.000 | 2.134 | 0.855 |
组别 | 例数 | WBC(×109/L) | 血红蛋白(g/L) | 血小板(×109/L) | Neu(×109/L) | Neu百分比(%) |
---|---|---|---|---|---|---|
血流感染组 | 144 | 12.32±6.22 | 103.98±24.38 | 189.37±105.24 | 10.87±6.12 | 84.91±10.11 |
对照组 | 140 | 9.76±4.80 | 107.27±28.09 | 210.77±97.48 | 8.25±8.09 | 79.48±9.83 |
t值 | 4.378 | 1.146 | 1.898 | 3.394 | 4.942 | |
P值 | 0.000 | 0.253 | 0.059 | 0.001 | 0.000 | |
组别 | 例数 | Lym(×109/L) | Lym百分比(%) | NLR | PCT(ng/mL) | CRP(mg/L) |
血流感染组 | 144 | 0.79(0.49~1.13) | 6.70(4.30~12.40) | 12.90(6.54~21.20) | 1.69(0.43~7.45) | 81.15±65.09 |
对照组 | 140 | 1.08(0.73~1.58) | 13.25(7.40~19.37) | 5.97(3.45~11.74) | 0.26(0.05~0.69) | 83.08±60.30 |
t值 | 4.740 | 6.610 | 6.768 | 2.134 | 0.183 | |
P值 | 0.000 | 0.000 | 0.000 | 2.134 | 0.855 |
项目 | ROC曲线下面积 | 标准误 | P值 | 95%可信区间 | |
---|---|---|---|---|---|
下限 | 上限 | ||||
WBC | 0.658 | 0.032 | 0.000 | 0.594 | 0.721 |
Neu | 0.702 | 0.031 | 0.000 | 0.641 | 0.763 |
Neu百分比 | 0.707 | 0.031 | 0.000 | 0.648 | 0.767 |
NLR | 0.740 | 0.029 | 0.000 | 0.682 | 0.797 |
PCT | 0.775 | 0.028 | 0.000 | 0.721 | 0.829 |
Neu百分比/Lym百分比比值 | 0.738 | 0.029 | 0.000 | 0.681 | 0.796 |
Lym | 0.653 | 0.030 | 0.000 | 0.595 | 0.712 |
Lym百分比 | 0.713 | 0.028 | 0.000 | 0.658 | 0.768 |
项目 | ROC曲线下面积 | 标准误 | P值 | 95%可信区间 | |
---|---|---|---|---|---|
下限 | 上限 | ||||
WBC | 0.658 | 0.032 | 0.000 | 0.594 | 0.721 |
Neu | 0.702 | 0.031 | 0.000 | 0.641 | 0.763 |
Neu百分比 | 0.707 | 0.031 | 0.000 | 0.648 | 0.767 |
NLR | 0.740 | 0.029 | 0.000 | 0.682 | 0.797 |
PCT | 0.775 | 0.028 | 0.000 | 0.721 | 0.829 |
Neu百分比/Lym百分比比值 | 0.738 | 0.029 | 0.000 | 0.681 | 0.796 |
Lym | 0.653 | 0.030 | 0.000 | 0.595 | 0.712 |
Lym百分比 | 0.713 | 0.028 | 0.000 | 0.658 | 0.768 |
项目 | 敏感性 | 特异性 | 阳性预测值 | 阴性预测值 |
---|---|---|---|---|
PCT | 55.2 | 85.0 | 78.6 | 65.5 |
NLR | 57.3 | 80.7 | 75.5 | 65.6 |
NLR+PCT | 67.1 | 76.4 | 73.8 | 69.4 |
项目 | 敏感性 | 特异性 | 阳性预测值 | 阴性预测值 |
---|---|---|---|---|
PCT | 55.2 | 85.0 | 78.6 | 65.5 |
NLR | 57.3 | 80.7 | 75.5 | 65.6 |
NLR+PCT | 67.1 | 76.4 | 73.8 | 69.4 |
[1] | CLEC'H C,FERRIERE F,KAROUBI P,et al. Diagnostic and prognostic value of procalcitonin in patients with septic shock[J]. Crit Care Med,2004,32(5):1166-1169. |
[2] | KARLSSON S,HEIKKINEN M,PETTILA(··) V,et al. Predictive value of procalcitonin decrease in patients with severe sepsis:a prospective observational study[J]. Crit Care,2010,14(6):R205. |
[3] | CHARLES PE,LADOIRE S,AHO S,et al.Serum procalcitonin elevation in critically ill patients at the onset of bacteremia caused by either Gram negative or Gram positive bacteria[J]. BMC Infect Dis,2008,8:38. |
[4] | SIMON L,GAUVIN F,AMRE DK,et al.Serum procalcitonin and C-reactive protein levels as markers of bacterial infection:a systematic review and meta-analysis[J]. Clin Infect Dis,2004,39(2):206-217. |
[5] | RINTALA EM,AITTONIEMI J,LAINE S,et al.Early identification of bacteremia by biochemical markers of systemic inflammation[J]. Scand J Clin Lab Invest,2001,61(7):523-530. |
[6] | JONES AE,FIECHTL IF,BROWN MD,et a1. Procalcitonin test in the diagnosis of bacteremia:a meta-analysis[J]. Ann Emerg Med,2007,50(1):34-41. |
[7] | 钟倩怡,李招云,卢国光,等. 感染性标志物预测血流感染早期诊断价值的分析[J]. 检验医学,2015,30(5):522-524. |
[8] | 侯伟伟,肖倩茹,江涟,等. 血清降钙素原作为菌血症预示因子临床价值的研究[J]. 检验医学,2014,29(8):802-805. |
[9] | HAWKINS CA,COLLIGNON P,ADAMS DN,et al.Profound lymphopenia and bacteraemia[J]. Intern Med J,2006,36(6):385-388. |
[10] | JILMA B,BLANN A,PERNERSTORFER T,et al.Regulation of adhesion molecules during human endotoxemia. No acute effects of aspirin[J]. Am J Respir Crit Care Med,1999,159(3):857-863. |
[11] | ZAHOREC R.Ratio of neutrophil to lymphocyte counts-rapid and simple parameter of systemic inflammation and stress in critically ill[J]. Bratisl Lek Listy,2001,102(1):5-14. |
[12] | VINCENT JL,MORENO R,TAKALA J,et al.The SOFA(sepsis-related organ failure assessment) score to describe organ dysfunction/failure. On behalf of the working group on sepsis-related problems of the European society of intensive care medicine[J]. Intensive Care Med,1996,22(7):707-710. |
[13] | GIBSON PH,CROAL BL,CUTHBERTSON BH,et al.Preoperative neutrophil-lymphocyte ratio and outcome from coronary artery bypass grafting[J]. Am Heart J,2007,154(5):995-1002. |
[14] | HALAZUN KJ,ALDOORI A,MALIK HZ,et al.Elevated preoperative neutrophil to lymphocyte ratio predicts survival following hepatic resection for colorectal liver metastases[J]. Eur J Surg Oncol,2008,34(1):55-60. |
[15] | TAMHANE UU,ANEJA S,MONTGOMERY D,et al.Association between admission neutrophil to lymphocyte ratio and outcomes in patients with acute coronary syndrome[J]. Am J Cardiol,2008,102(6):653-657. |
[16] | HALAZUN KJ,HARDY MA,RANA AA,et al.Negative impact of neutrophil-lymphocyte ratio on outcome after liver transplantation for hepatocellular carcinoma[J]. Ann Surg,2009,250(1):141-151. |
[1] | FAN Lieying. Research status and application prospects of biomarkers for membranous nephropathy [J]. Laboratory Medicine, 2023, 38(12): 1111-1114. |
[2] | SUN Lincheng, LI Jianfeng, CHENG Weili, JI Panyun. Roles of anti-PLA2R IgG4 antibody and PLA2R IgG4/IgG ratio in primary membranous nephropathy [J]. Laboratory Medicine, 2023, 38(12): 1115-1120. |
[3] | LIU Qingyang, YUAN Jianming, XIA Jinjun, JIANG Fengying, WANG Qiubo, WANG Xiaoming. CXCL9 as a potential diagnostic marker of rheumatoid arthritis based on GEO database and experimental verification [J]. Laboratory Medicine, 2023, 38(12): 1121-1129. |
[4] | YANG Xiao, LI Enling, WU Lixia, DAI Yingxin, WANG Zhiqing, HUANG Hao, ZHENG Bing. Influence of cytoplasmic antinuclear antibody on indirect immunofluorescence assay based antineutrophil cytoplasmic antibody determination [J]. Laboratory Medicine, 2023, 38(12): 1135-1140. |
[5] | XIANG Jin, LIU Aiping, HU Yao, WU Zhiyuan, CAO Guojun, GUAN Ming. ANA profiles in COVID-19 patients and influence of serum heat-inactivation on ANA determination [J]. Laboratory Medicine, 2023, 38(12): 1141-1146. |
[6] | CHENG Yu, XU Zhen, LU Liu, DING Menglei, YU Shanshan, ZONG Ming, FAN Lieying. Expression and risk factors of anti-ACE-2 antibody in serum of patients with COVID-19 [J]. Laboratory Medicine, 2023, 38(12): 1147-1152. |
[7] | . [J]. Laboratory Medicine, 2023, 38(12): 1153-1156. |
[8] | . [J]. Laboratory Medicine, 2023, 38(12): 1157-1159. |
[9] | WANG Hongling, LIU Mengna, BAI Ping, LIAO Huanjin. Risk factors of relapse following allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia [J]. Laboratory Medicine, 2023, 38(12): 1160-1166. |
[10] | YANG Xilan, WANG Jinyu, LIU Shuyu, ZHAN Yiyang, LIU Jing, JIA Jian. Correlation between hyperlipidemia and endothelial microparticles in elderly patients from Gulou Community in Nanjing [J]. Laboratory Medicine, 2023, 38(12): 1167-1172. |
[11] | DAI Fangfang, LU Xinxin, YU Yanhua, CHEN Ming, SUN Guizhen. Analysis of Mycobacterium infection in HIV/AIDS patients [J]. Laboratory Medicine, 2023, 38(12): 1173-1176. |
[12] | GU Yu, LIANG Xiaoyan, MA Shenghui, TONG Na, CHENG Mingyan, YAN Zejun. Expression and near-term prognostic predictive value of plasma biomarkers in chronic kidney disease patients with thromboembolism [J]. Laboratory Medicine, 2023, 38(12): 1177-1182. |
[13] | . [J]. Laboratory Medicine, 2023, 38(12): 1183-1185. |
[14] | . [J]. Laboratory Medicine, 2023, 38(12): 1186-1190. |
[15] | . [J]. Laboratory Medicine, 2023, 38(12): 1191-1194. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||